FOSPET predicts VA

Article

Foveal outer segment/pigment epithelial thickness (FOSPET) is significantly thinner in patients with retinitis pigmentosa (RP) than in normal eyes and also shows correlation in logMAR visual acuity (VA), indicating it may be a predictor of VA in RP, according to a study published in the December 2006 issue of the American Journal of Ophthalmology.

Foveal outer segment/pigment epithelial thickness (FOSPET) is significantly thinner in patients with retinitis pigmentosa (RP) than in normal eyes and also shows correlation in logMAR visual acuity (VA), indicating it may be a predictor of VA in RP, according to a study published in the December 2006 issue of the American Journal of Ophthalmology.

Andre Witkin, MD from the New England Eye Center, Boston, USA and colleagues, conducted an observational case series of nine eyes of nine patients with RP and related diseases which were imaged using ultra-high resolution optical coherence tomography (UHR-OCT). Concurrently, 36 eyes of 36 normal subjects were also imaged this way. Central foveal thickness (CFT) and FOSPET were defined and measured on UHR-OCT images in all subjects and were compared between the two groups using unpaired t tests. The two thickness measurements in RP subjects were correlated with VA using Pearson correlation and linear regression.

The UHR-OCT images showed macular photoreceptor thinning in all RP subjects. The difference in CFT between the two groups was not statistically significant (p=0.103), however the difference in FOSPET was (p=0.003). VA showed some correlation with CFT (Pearson r=0.43, r2=0.187, p=0.245) and a strong correlation with FOSPET (Pearson r=0.942, r2=0.887, p<0.0001).

The researchers believe that FOSPET may represent a possible predictor of VA in patients with RP.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.